Presented at the European Academy of Allergy and Clinical Immunology, 31 May–3 June, 2024, Valencia, Spain
Massimo Triggiani, Ruben Mesa, Cristina Bulai Livideanu, Amélie Beaux, Jessica Hobart, Nicole Hegmann, Waltraud Schinhofen, Iván Alvarez-Twose, Eugenia Ribada, Celeste C Finnerty, Coralie Gressier-Sayag, Dakota Powell, Teresa Green, Deepti H Radia, Franziska Ruëff
Introduction
• Systemic mastocytosis (SM) is a clonal mast cell disease primarily driven by the KIT D816V mutation and characterized by unpredictable and debilitating symptoms
• SM consists of two distinct groups of variants, advanced and non-advanced; AdvSM includes aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia; non-AdvSM includes indolent SM and smoldering SM
• Previously, a United States (US)-based survey study (Touchstone) reported insights from health care professionals (HCPs) treating patients with SM. In that survey, responses from 111 HCPs revealed that SM diagnosis in the US is challenging and often delayed, involving a variety of specialists, notably allergists/immunologists (A/Is) and hematologists/oncologists (H/Os)
• There is limited insight regarding HCP profiles and their perceptions on the diagnosis and management of patients with SM in Europe and the UK
• The Perceptions Realities and Insights on Systemic Mastocytosis (PRISM) survey study examined experiences of patients with SM and perspectives from HCPs treating SM in Europe and the UK
• Here, we report data from PRISM on the impact of SM on patients from an HCP perspective
 |
Virus-free.www.avast.com |
Mastopedia Research Feed 